<DOC>
	<DOCNO>NCT01368848</DOCNO>
	<brief_summary>Despite recent advance treatment NSCLC overall survival within patient remain dismal yet unmet medical need additional treatment option . In phase II study combination chemotherapy antibody ( cisplatin , docetaxel bevacizumab ) test determine objective response rate patient unresectable advanced non-small cell lung cancer . This response rate compare historical data .</brief_summary>
	<brief_title>Combination Cisplatin , Docetaxel Bevacizumab Patients With Non-small Cell Lung Carcinoma ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically document inoperable , locally advanced , metastatic recurrent NSCLC squamous cell At least 1 measurable lesion accord RECIST criterion ECOG performance score 0 1 Age 18 70 year Mixed , nonsmall cell small cell tumour mix adenosquamous carcinoma predominant squamous component . History haemoptysis Evidence tumour invade major blood vessel image . Previous neoadjuvant/adjuvant chemotherapy . Previous radiotherapy . Serious uncontrolled coagulation disorder thromboembolic complication within 6 month prior study start history serious bleeding complication . Major surgical procedure within 4 week prior study entry . Minor surgery , include insertion indwelling catheter , within 24 hour prior first bevacizumab infusion . Nonhealing wound , active peptic ulcer bone fracture . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>AGMT</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Inoperable</keyword>
	<keyword>stage IIIB IV</keyword>
</DOC>